Compare Nasdaq Inc (NDAQ) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs Viatris Inc — how do they compare? Nasdaq Inc trades at $95.81 (market cap $53.11B), while Viatris Inc trades at $16.11 (market cap $18.69B). The key difference: Nasdaq Inc is far larger — about 2.8× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| NDAQ | VTRS | |
|---|---|---|
Market Cap | $53.11B | $18.69B |
Sector | Financials | Health |
52-Week High | $100.98 | $17.86 |
52-Week Low | $76.85 | $9.49 |
Enterprise Value | $59.57B | $30.80B |
Dividend Yield | 1.22% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq (NDAQ) trades at $95.26, down 0.38% on the day, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $8.26B in 2025, with net income reaching $1.79B and a profit margin of 21.64%. The company has beaten EPS estimates in recent quarters and announced the acquisition of LeveL Markets to expand its market infrastructure. Analyst consensus is strongly positive, with a $109.20 price target indicating ~15% upside.
Outlook remains favorable driven by earnings growth and strategic acquisitions, though risks include market volatility and integration challenges. The stock offers value through consistent profitability and dividend payments, supported by institutional confidence. Investors should weigh execution risks against the potential for continued expansion in financial services technology.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
